Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care

Public Health Genomics

Volumn 18, Issue 6, 2015, Pages 349-358

  Schneider, Daniel ^a   Bianchini, Giampaolo ^b   Horgan, Denis ^c   Michiels, Stefan ^d   Witjes, Wim ^e   Hills, Robert ^g   Plun Favreau, Juliette ^a   Brand, Angela ^f   Lawler, Mark ^h  

^a Genomic Health International   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c European Alliance for Personalised Medicine   (Belgium)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e Italy   (Netherlands)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Biomarkers; Clinical utility; Companion diagnostic; Molecular diagnostics; Personalised medicine; Policy; Regulatory requirements; Validation

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER CARE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST APPROVAL; DIAGNOSTIC VALUE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; MOLECULAR DIAGNOSIS; PATIENT CARE; PERSONALIZED MEDICINE; POPULATION RESEARCH; PRIORITY JOURNAL; REIMBURSEMENT; VALIDATION STUDY; ECONOMICS; EUROPEAN UNION; METABOLISM; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; REPRODUCIBILITY; STANDARDS;

BIOMARKERS, TUMOR; EUROPEAN UNION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATHOLOGY, MOLECULAR; PRECISION MEDICINE; REPRODUCIBILITY OF RESULTS;

EID: 84952872394     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000441556     Document Type: Article

References (42)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
2. European Medicines Agency: Approvals. London, European Medicines Agency 2015.
3. Statista: Number of cancer drugs in development in the United States from 2005 to 2014. New York, Statista, 2015.
4. Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F: Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(suppl 6):vi7-vi23.
5. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios C, Bergh J, Biganzoli L, Blackwell K: ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Breast 2014; 23: 489-502.
6. Labianca R, Nordlinger B, Beretta G, Mosconi S, Mandala M, Cervantes A, Arnold D, Group EGW: Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(suppl 6):vi64-vi72.
7. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr K, Peters S: Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 2014; 25(suppl 3):iii27-iii39.
8. Horwich A, Parker C, De Reijke T, Kataja V, Group EGW: Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(suppl 6):vi106-vi114.
9. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL: Breaking a vicious cycle. Sci Transl Med 2013; 5: 196cm6.
10. Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM: Validation of new cancer biomarkers: a position statement from the European Group on Tumor Markers. Clin Chem 2015; 61: 809-820.
11. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
12. Björkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjöberg J, Andersson T, Höglund M, Richter J, Landgren O: Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514-2520.
13. Djalalov S, Beca J, Hoch JS, Krahn M, Tsao M-S, Cutz J-C, Leighl NB: Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 2014; 32: 1012-1019.
14. Aisner DL, Marshall CB: Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol 2012; 138: 332-346.
15. Chouaïd C, Crequit P, Borget I, Vergnenegre A: Economic evaluation of first-line and maintenance treatments for advanced nonsmall cell lung cancer: a systematic review. Clinicoecon Outcomes Res 2015; 7: 9.
16. Nowak F, Soria J-C, Calvo F: Tumour molecular profiling for deciding therapy-The French Initiative. Nat Rev Clin Oncol 2012; 9: 479-486.
17. Simon R: Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005; 23: 7332-7341.
18. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
19. Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjö A, Rouleau E, Solé F, Thunnissen E, Timens W, Schuuring E: Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 2014; 67: 923-931.
20. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010; 56:e1-e48.
21. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley M-YC, Kim KY, Tricoli JV: Criteria for the use of omics-based predictors in clinical trials. Nature 2013; 502: 317-320.
22. Altman DG, McShane LM, Sauerbrei W, Taube SE: Reporting recommendations for tumor marker prognostic studies (remark): explanation and elaboration. BMC Med 2012; 10: 51.
23. Hall JA, Salgado R, Lively T, Sweep F, Schuh A: A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. Lancet Oncol 2014; 15:e184-e193.
24. Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, DeVerka P, Frueh FW, Jessup JM: Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 2014; 20: 1428-1444.
25. Khleif SN, Doroshow JH, Hait WN: AACRFDA-NCI cancer biomarkers collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010; 16: 3299-3318.
26. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C: Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer 2015; 51: 271-281.
27. Lawler M, Kaplan R, Wilson RH, Maughan T, Consortium S-C: Changing the paradigm-multistage multiarm randomized trials and stratified cancer medicine. Oncologist 2015; 20: 849-851.
28. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
29. Diamandis EP: Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010; 102: 1462-1467.
30. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010; 28: 2784-2795.
31. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11: 3-14.
32. Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F: The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2009; 77: 57-68.
33. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
34. Markopoulos C: Overview of the use of Oncotype DX as an additional treatment decision tool in early breast cancer. Expert Rev Anticancer Ther 2013; 13: 179-194.
35. Sparano JA, Gray RJ, Makower DF, et al: Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015, Epub ahead of print.
36. Canfield SE, Kibel AS, Kemeter MJ, Febbo PG, Lawrence HJ, Moul JW: A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. Rev Urol 2014; 16: 172.
37. Skates SJ: A statistical challenge: developing tests for biomarker utility specific to the intended use. J Natl Cancer Inst 2014; 106: dju076.
38. Towse A, Ossa D, Veenstra D, Carlson J, Garrison L: Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. J Pers Med 2013; 3: 288-305.
39. European Alliance for Personalised Medicine: Innovation and Patient Access to Personalised Medicine. Brussels, European Alliance for Personalised Medicine, 2013.
40. Newland A: NICE diagnostics assessment programme. Ann R Coll Surg Engl 2011; 93: 412.
41. National Institute for Clinical Excellence: Diagnostic Assessment Programme Manual. London, National Institute for Clinical Excellence, 2011.
42. European Commission: Use of '-omics' Technologies in the Development of Personalised Medicine. Brussels, European Commission, 2013.